翻訳と辞書 |
Galápagos NV : ウィキペディア英語版 | Galápagos NV
Galápagos NV is a Belgian pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell and Tibotec.〔http://www.glpg.com/index.php/aboutus/aboutus/〕 Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe. ==Drugs currently under development==
*Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease. *GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease. *GLPG0778 and GLPG0555: a drug developed in alliance with GlaxoSmithKline and currently being researched as a treatment agenst systemic lupus erythematosus, psoriasis and ulcerative colitis.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Galápagos NV」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|